1.	A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 03411, NCT01497795
2.	Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 813320, NCT01676831
3.	Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SP848-nBCC-1104, NCT01808950
4.	Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0416, NCT00960752
5.	Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SP848-AK-1101, NCT01583816
6.	Observational Trial Assessing Long-term Local Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis. Phase: No phase specified Type: Natural history/Epidemiology Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SP848-AKEx-1209, NCT01806961